Propriétés antitumorales du bisphosphonate zolédronate et implications thérapeutiques potentielles en clinique |
| |
Institution: | 1. Department of Pediatric Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands;2. Princess Máxima Center for Pediatric Oncology, Wilhelmina Children''s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands |
| |
Abstract: | Zoledronate, just as other bisphosphonates, inhibit osteoclast mediated bone resorption. This is the reason why they are used in the treatment of bone metastasis, in order to block osteolysis. Zoledronate and some other bisphosphonates (clodronate, pamidronate, ibandronate, alendronate, risédronate, minodronate) also exhibit antitumor properties in vitro. They act directly on tumor cells by blocking tumor cell adhesion, invasion and proliferation, and by inducing tumor cell apoptosis. However, their high bone mineral affinity decreases their bioavailability to a significant extent and, thus, should weaken their in vivo antitumor potential. Despite of this, several studies (most of them being performed with zoledronate) show that bisphosphonates have an in vivo antitumor activity. This review focuses on zoledronate and on results obtained in several experimental models showing that this bisphosphonate interferes with the growth of tumors and metastases which are thriving in tissues others than the skeletal tissue. The significance of these findings is discussed in the light of several ongoing clinical trials which examine the benefits of using zoledronate and other bisphosphonates in the adjuvant treatment of cancers at an early stage of the disease. |
| |
Keywords: | bisphosphonate zolédronate cancer métastase tissu osseux lymphocyte T γδ bisphosphonate zoledronate cancer metastasis bone γδ T lymphocyte |
本文献已被 ScienceDirect 等数据库收录! |
|